Core Viewpoint - Aohua Endoscopy experienced a decline of 3.21% in stock price on December 23, with a trading volume of 69.16 million yuan, indicating potential investor concerns regarding the company's financial performance and market position [1]. Financing and Trading Data - On December 23, Aohua Endoscopy had a financing buy-in amount of 8.64 million yuan, with a net financing buy of 5.35 million yuan after repayments [1]. - The total financing and securities balance reached 128 million yuan, accounting for 2.11% of the circulating market value, which is above the 80th percentile of the past year, indicating a high level of financing activity [1]. - The company had no short selling activity on December 23, with a short selling balance of 28.72 thousand yuan, also above the 90th percentile of the past year [1]. Financial Performance - For the period from January to September 2025, Aohua Endoscopy reported a revenue of 423 million yuan, a year-on-year decrease of 15.57%, and a net profit attributable to shareholders of -56.09 million yuan, reflecting a significant decline of 250.37% [2]. - Cumulative cash dividends since the company's A-share listing amount to 76.28 million yuan, with 50.95 million yuan distributed over the past three years [3]. Shareholder Structure - As of September 30, 2025, the number of shareholders increased by 41.52% to 5,549, while the average circulating shares per person decreased by 29.34% to 24,268 shares [2]. - Among the top ten circulating shareholders, notable changes include an increase in holdings by the third-largest shareholder, with a 50.55 thousand share increase, while other funds reduced their holdings [3].
澳华内镜12月23日获融资买入863.97万元，融资余额1.28亿元